Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Ogbebor, Osakpolor; Seth, Harshit; Min, Zaw; Bhanot, Nitin

doi:10.1016/j.idcr.2021.e01143

Cited by 38 publications

(23 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Altogether nine articles reporting 18 patients with SCoVaG were noted (3)(4)(5)(6)(7)(8)(9)(10)(11). A study on one more patient has not been published yet.…”

Section: ' Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Finsterer¹,

Scorza²,

Scorza³

2021

Clinics

View full text Add to dashboard Cite

SARS-CoV-2 vaccinations are not free from side effects. Usually, they are mild or moderate but occasionally severe. One of these severe side effects is Guillain-Barre ´syndrome (GBS). This review summarizes and discusses GBS as a side effect of SARS-CoV-2 vaccinations (SCoVaG) based on recent research reports. Altogether, nine articles reporting 18 patients with SCoVaG were identified and one more report on another patient is under review. The age for the studies ranged between 20-86y. Nine patients were male, and ten were female. In all 19 patients, SCoVaG developed after the first dose of the vaccine. The Astra Zeneca vaccine was used in fourteen patients, the Pfizer vaccine in four patients, and the Johnson & Johnson vaccine was applied in one patient. The latency between vaccination and onset of GBS ranged from 3h to 39d. The treatment of SCoVaG included IVIGs (n=13), steroids (n=3), or no therapy (n=3). Six patients required mechanical ventilation. Only a single patient recovered completely and partial recovery was achieved in nine patients. In conclusion, GBS may develop time-linked to the first dose of a SARS-CoV-2 vaccination. Though a causal relationship between SARS-CoV-2 vaccinations and SCoVaG remains speculative, more evidence is in favour than against it.

show abstract

“…Altogether nine articles reporting 18 patients with SCoVaG were noted (3)(4)(5)(6)(7)(8)(9)(10)(11). A study on one more patient has not been published yet.…”

Section: ' Resultsmentioning

confidence: 99%

“…The seventh patient with SCoVaG is an 86y old female diagnosed with GBS one day after receiving the first dose of an mRNA-based SARS-CoV-2 vaccine (Table 1) (5). She recovered only partially under IVIGs (5) and did not require mechanical ventilation.…”

Section: ' Resultsmentioning

confidence: 99%

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Finsterer¹,

Scorza²,

Scorza³

2021

Clinics

View full text Add to dashboard Cite

show abstract

“…7 So far, these numbers do not exceed the natural expected case rates, although reports continue to be closely monitored. Similarly, there are only individual case reports of neurological adverse events following COVID-19 vaccines in the literature; these include GBS, 44 Bell's palsy, 45 acute disseminated encephalomyelitis (ADEM), 46 transverse myelitis, 47 delirium 48 and seizures. 49 The authors of these articles warn against attributing causality based solely on the temporal association.…”

Section: Postapproval Surveillancementioning

confidence: 99%

Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder

Butler¹,

Tamborska

Wood

et al. 2021

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

“…Until 1 December 2021, we identified a total of 24 case reports and 16 publications, [221][222][223][224][225][226][227][228][229][230][231][232][233][234][235][236] with the majority of cases occurring after the AstraZeneca vaccine (17 out of 24). 222,224,225,[229][230][231][232]235,236 Initial reports included two patients with classic AIDP occurring 11 and 14 days after the first dose of the ChAdOx1c nCoV-19 vaccine (AstraZeneca).…”

Section: Cov2s (Johnson and Johnsonmentioning

confidence: 99%

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Taga

Lauria

2022

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Increasing literature has linked COVID‐19 to peripheral nervous system (PNS) diseases. In addition, as we move from the pandemic to the vaccination era, literature interest is shifting towards the potential association between COVID‐19 vaccines and PNS manifestations. We reviewed published literature on COVID‐19, COVID‐19 vaccines and PNS manifestations between 1 January 2020 and 1 December 2021. For Guillain‐Barré syndrome (GBS), isolated cranial neuropathy (ICN) and myositis associated with COVID‐19, the demographic, clinical, laboratory, electrophysiological and imaging features were included in a narrative synthesis. We identified 169 studies on COVID‐19‐associated complications, including 63 papers (92 patients) on GBS, 29 papers (37 patients) on ICN and 11 papers (18 patients) on myositis. Additional clinical phenotypes included chronic inflammatory demyelinating polyneuropathy, vasculitic neuropathies, neuralgic amyotrophy, critical care‐related complications, and myasthenia gravis. PNS complications secondary to COVID‐19 vaccines have been reported during randomized clinical trials, in real‐world case reports, and during large‐scale surveillance programs. These mainly include cases of GBS, Bell's palsy, and cases of neuralgic amyotrophy. Based on our extensive review of the literature, any conclusion about a pathophysiological correlation between COVID‐19 and PNS disorders remains premature, and solely supported by their temporal association, while epidemiological and pathological data are insufficient. The occurrence of PNS complications after COVID‐19 vaccines seems limited to a possible higher risk of facial nerve palsy and GBS, to a degree that widespread access to the ongoing vaccination campaign should not be discouraged, while awaiting for more definitive data from large‐scale surveillance studies.

show abstract

Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association

Cited by 38 publications

References 7 publications

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients

Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Contact Info

Product

Resources

About